Leveraging a CDMO’s established platform for AAV manufacturing can significantly streamline gene therapy development.

Plasmid and AAV Manufacturing Partnership to Advance Myrtelle’s Novel Gene Therapy for Monogenic Hearing Loss for Phase 1/2 Clinical Trials October 03, 2022 08:00 AM Eastern Daylight Time ...

Identifying Viral Vector Characteristics by Nanopore Sensing. ACS Nano, 2024; 18 (24): 15695 DOI: 10.1021/acsnano.4c01888 ...

CDMOs account for over 60% of outsourced viral vector manufacturing services. The demand for GMP-grade plasmid DNA has surged by over 200% since 2021. FDA approvals for gene therapies doubled between ...

One of the landmark breakthroughs in gene therapy occurred when three clinical trials evaluated the efficacy of adeno-associated virus serotype 2 vectors carrying a functional copy of the retinal ...

Gene therapies can correct diseases at their genetic core, but their success hinges on viral vector manufacturing. | Explore the tales of one emerging and one established company seeking contract ...

In this case, the company tested a vector based on a virus from the Betatorquevirus genus. In the new study, Ring tested its Anellovector’s ability to deliver a gene expressing a fluorescent ...

PAL-treated macaques had one-fourth of the viral material in their livers as AAV9-treated primates did, suggesting that the new capsids could help limit the liver toxicity of other gene therapies.

Andres-Mateos, E., et al. (2022) Choice of vector and surgical approach enables efficient cochlear gene transfer in nonhuman primate. Nature Communications. doi.org/10.1038/s41467-022-28969-3.

Viruses naturally reproduce by transferring genetic material into cells for transcription and translation. Scientists harness this ability to introduce genetic sequences and modulate cellular function ...

Alexandria Forbes, PhD, CEO, MeiraGTx The degree of vector optimization at MeiraGTx differentiates it from other gene therapy developers. Its gene therapy platform, which optimizes capsids and ...

Pointing to a few empty chairs in a conference room, moderator David T. Curiel joked that a symposium on emerging nonviral vectors was a "failure" compared to other packed talks at the American ...